The Mark Foundation for Cancer Research is an investor in Accent Therapeutics, a Boston-area platform biopharmaceutical company focused on RNA-modifying proteins (RMPs) implicated in cancer. Accent is developing small molecule inhibitors of promising targets within this space. The rich pipeline of programs at Accent has the potential to deliver multiple new therapies to patients across a variety of cancer indications, including hematologic and solid tumors.
The Mark Foundation for Cancer Research is an investor in C2i Genomics, a company based in NYC and Israel developing ultra-sensitive liquid biopsy technologies. C2i spun out of foundational research at Weill Cornell Medicine and the New York Genome Center that was funded by a 2018 ASPIRE award from The Mark Foundation. By combining the power of whole genome sequencing and proprietary machine learning algorithms, C2i aims to provide a personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers throughout multiple cycles of care.
The Mark Foundation for Cancer Research is an investor in GRAIL, a California-based healthcare company focused on developing technologies for the early detection of cancer. Aligned with our mission to fund groundbreaking research integrating discoveries in biology with innovative technology, The Mark Foundation expects that this investment will accelerate the development of early detection technologies that have the potential to reduce cancer deaths globally.
The Mark Foundation for Cancer Research is an investor in Interius Biotherapeutics, a next generation in vivo cell reprogramming company located in Philadelphia. Interius is developing technologies initially conceived as the basis for an Emerging Leader Award (ELA) from the Mark Foundation to Saar Gill, MD, PhD, from the University of Pennsylvania. Support from the Mark Foundation directly resulted in key inventions forming the basis for further work. Interius is initially focused on realizing dramatic improvements in the safety and accessibility of cell therapies for patients with B cell malignancies.
The Mark Foundation for Cancer Research is an investor in Boston-based Verseau Therapeutics, a company which develops MAcrophage Phenotype Switching Immunotherapeutics (MAPS) that can activate or de-activate a patient‘s immune system. Verseau MAPS Immunotherapies induce a comprehensive anti-tumor immune response in a wide patient population. The Mark Foundation expects that these therapies will broaden the patient population that can benefit from immunotherapy.